BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.

The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency ...

Spinal muscular atrophy (SMA) is a rare, genetic condition that, across all types, affects ~1,600 people in the UK.1 It can cause muscle weakness which gets worse over time, causing movement, ...

This high dose nusinersen regimen for spinal muscular atrophy includes 50 mg loading doses and 28mg maintenance doses.

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm. The ...

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in that area, it serves as strong validation of the partner’s technology. It’s ...

Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and research and development activities. Before market open, ...

Biogen has entered into a multi-target partnership with Alloy Therapeutics to leverage Alloy’s AntiClastic™ ASO technology for developing antisense therapeutics. Financial terms include upfront ...

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in ...